Search Results - "Ritchey, K."

A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity by Kim, Miriam Y., Jayasinghe, Reyka, Devenport, Jessica M., Ritchey, Julie K., Rettig, Michael P., O’Neal, Julie, Staser, Karl W., Kennerly, Krista M., Carter, Alun J., Gao, Feng, Lee, Byung Ha, Cooper, Matthew L., DiPersio, John F.

“…Chimeric antigen receptor (CAR) T cell therapy is routinely used to treat patients with refractory hematologic malignancies. However, a significant proportion…”
Get full text

Task-Oriented Reading: A Framework for Improving College Students' Reading Compliance and Comprehension by Ritchey, K. A., List, A.

“…Undergraduates report a variety of reasons for not reading assigned text(s), including confusion regarding instructors' expectations, while faculty report…”
Get full text

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100 by Nervi, Bruno, Ramirez, Pablo, Rettig, Michael P., Uy, Geoffrey L., Holt, Matthew S., Ritchey, Julie K., Prior, Julie L., Piwnica-Worms, David, Bridger, Gary, Ley, Timothy J., DiPersio, John F.

“…The CXCR4–SDF-1 axis plays a central role in the trafficking and retention of normal and malignant stem cells in the bone marrow (BM) microenvironment. Here,…”
Get full text

Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager by Eissenberg, Linda G, Ritchey, Julie K, Rettig, Michael P, Patel, Dilan A, Vij, Kiran, Gao, Feng, Smith, Victoria, Han, Tae H, DiPersio, John F

“…Off-the-shelf immunotherapeutics that suppress tumor growth and provide durable protection against relapse could enhance cancer treatment. We report…”
Get full text

Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells by Karpova, Darja, Ritchey, Julie K., Holt, Matthew S., Abou-Ezzi, Grazia, Monlish, Darlene, Batoon, Lena, Millard, Susan, Spohn, Gabriele, Wiercinska, Eliza, Chendamarai, Ezhil, Yang, Wei, Christ, Stephanie, Gehrs, Leah, Schuettpelz, Laura G., Dembowsky, Klaus, Pettit, Allison R., Rettig, Michael P., Bonig, Halvard, DiPersio, John F.

“…Interaction between the chemokine receptor CXCR4 and its chief ligand CXCL12 plays a critical role in the retention and migration of hematopoietic stem and…”
Get full text

BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells by Ramirez, Pablo, Rettig, Michael P., Uy, Geoffrey L., Deych, Elena, Holt, Matthew S., Ritchey, Julie K., DiPersio, John F.

“…Here we show that interruption of the VCAM-1/VLA-4 axis with a small molecule inhibitor of VLA-4, BIO5192, results in a 30-fold increase in mobilization of…”
Get full text

CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy by Kim, Miriam Y, Cooper, Matthew L, Jacobs, Miriam T, Ritchey, Julie K, Hollaway, Julia, Fehniger, Todd A, DiPersio, John F

“…Targeting T cell malignancies with universal CD7-targeting chimeric antigen receptor T cells (UCART7) can lead to profound immune deficiency due to loss of…”
Get full text

Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis by Ghobadi, Armin, Rettig, Michael P., Cooper, Matthew L., Holt, Matthew S., Ritchey, Julie K., Eissenberg, Linda, DiPersio, John F.

Get full text

Targeting CXCR4, VLA-4, and CXCR2 for hematopoietic stem cell mobilization by Cancilla, Daniel, Rettig, Michael P., Karpova, Darja, Thakellapalli, Haresh, Singh, Megh, Meyers, Marvin J., Ruminski, Peter G., Christ, Stephanie, Chendamarai, Ezhilarasi, Gao, Feng, Gehrs, Leah, Ritchey, Julie K., Prinsen, Michael, DiPersio, John F.

Get full text

Benefits and constraints for use of FGD products on agricultural land by Clark, R.B, Ritchey, K.D, Baligar, V.C

“…Considerable amounts of coal combustion products (CCPs) are generated when coal is burned for generation of electricity. To meet Clean Air standards, large…”
Get full text

Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or Azathioprine by EVANS, William E, YUEN YI HON, MURRAY, Jeffrey, QUINN, John, RAVINDRANATH, Y, RITCHEY, Kim, ROBERTS, William, ROGERS, Zora R, SCHIFF, Deborah, STEUBER, Charles, TUCCI, Fabio, KORNEGAY, Nancy, BOMGAARS, Lisa, KRYNETSKI, Eugene Y, RELLING, Mary V, COUTRE, Steve, HOLDSWORTH, Mark, JANCO, Robert, KALWINSKY, David, KELLER, Frank, KHATIB, Ziad, MARGOLIN, Judy

“…To assess thiopurine S-methyltransferase (TPMT) phenotype and genotype in patients who were intolerant to treatment with mercaptopurine (MP) or azathioprine…”
Get full text

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies by Cooper, Matthew L, Choi, Jaebok, Staser, Karl, Ritchey, Julie K, Devenport, Jessica M, Eckardt, Kayla, Rettig, Michael P, Wang, Bing, Eissenberg, Linda G, Ghobadi, Armin, Gehrs, Leah N, Prior, Julie L, Achilefu, Samuel, Miller, Christopher A, Fronick, Catrina C, O’Neal, Julie, Gao, Feng, Weinstock, David M, Gutierrez, Alejandro, Fulton, Robert S, DiPersio, John F

“…T cell malignancies represent a group of hematologic cancers with high rates of relapse and mortality in patients for whom no effective targeted therapies…”
Get full text

[18F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility by Eissenberg, Linda G, Rettig, Michael P, Ritchey, Julie K, Prior, Julie L, Schwarz, Sally W, Frye, Jennifer, White, Brian S, Fulton, Robert S, Ghobadi, Armin, Cooper, Matthew L, Couriel, Daniel R, Seegulam, Muhammad Esa, Piwnica-Worms, David, Dehdashti, Farrokh, Cornetta, Kenneth, DiPersio, John F

“…Described herein is a first-in-man attempt to both genetically modify T cells with an imagable suicide gene and track these transduced donor T cells in…”
Get full text

Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research by Eapen, M, Zhang, M-J, Devidas, M, Raetz, E, Barredo, J C, Ritchey, A K, Godder, K, Grupp, S, Lewis, V A, Malloy, K, Carroll, W L, Davies, S M, Camitta, B M

“…In children with acute lymphoblastic leukemia (ALL) with isolated central nervous system (CNS) relapse and a human leucocyte antigen (HLA)-matched sibling, the…”
Get full text

Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform by Al-Hussaini, Muneera, Rettig, Michael P., Ritchey, Julie K., Karpova, Darja, Uy, Geoffrey L., Eissenberg, Linda G., Gao, Feng, Eades, William C., Bonvini, Ezio, Chichili, Gurunadh R., Moore, Paul A., Johnson, Syd, Collins, Lynne, DiPersio, John F.

“…T-cell–directed killing of tumor cells using bispecific antibodies is a promising approach for the treatment of hematologic malignancies. Here we describe our…”
Get full text

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing by Ding, Li, Ley, Timothy J., Larson, David E., Miller, Christopher A., Koboldt, Daniel C., Welch, John S., Ritchey, Julie K., Young, Margaret A., Lamprecht, Tamara, McLellan, Michael D., McMichael, Joshua F., Wallis, John W., Lu, Charles, Shen, Dong, Harris, Christopher C., Dooling, David J., Fulton, Robert S., Fulton, Lucinda L., Chen, Ken, Schmidt, Heather, Kalicki-Veizer, Joelle, Magrini, Vincent J., Cook, Lisa, McGrath, Sean D., Vickery, Tammi L., Wendl, Michael C., Heath, Sharon, Watson, Mark A., Link, Daniel C., Tomasson, Michael H., Shannon, William D., Payton, Jacqueline E., Kulkarni, Shashikant, Westervelt, Peter, Walter, Matthew J., Graubert, Timothy A., Mardis, Elaine R., Wilson, Richard K., DiPersio, John F.

“…The sequencing of AML genomes of eight patients before and after relapse reveals two major patterns of clonal evolution, with chemotherapy appearing to have a…”
Get full text

Anti-myeloma efficacy of BCMA CAR-iNKT is enhanced with a long-acting IL-7, rhIL7hyFc by O'Neal, Julie, Cooper, Matthew L., Ritchey, Julie K., Gladney, Susan, Niswonger, Jessica, Sofía González, L., Street, Emily, Haas, Gabriel J., Carter, Alun, Amayta, Parmeshwar N., Gao, Feng, Ha Lee, Byung, Choi, Donghoon, Berrien-Elliott, Melissa, Zhou, Alice, Fehniger, Todd A., Rettig, Mike P., DiPersio, John F.

Get full text

Interleukin 10 induced augmentation of delayed‐type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette‐Guérin (BCG) mediated antitumour activity by NADLER, R., LUO, Y., ZHAO, W., RITCHEY, J. K., AUSTIN, J. C., COHEN, M. B., O'DONNELL, M. A., RATLIFF, T. L.

“…SUMMARY Intravesical BCG therapy is effective in the treatment of superficial bladder cancer. Both clinical and experimental results suggest a role for…”
Get full text

An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies by Xiang, Jingyu, Devenport, Jessica M., Carter, Alun J., Staser, Karl W., Kim, Miriam Y., O’ Neal, Julie, Ritchey, Julie K., Rettig, Michael P., Gao, Feng, Rettig, Garrett, Turk, Rolf, Lee, Byung Ha, Cooper, Matthew L., DiPersio, John F.

“…T-cell malignancies are associated with frequent relapse and high morbidity, which is partly due to the lack of effective or targeted treatment options. To…”
Get full text

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells by Rimando, Joseph C., Chendamarai, Ezhilarasi, Rettig, Michael P., Jayasinghe, Reyka, Christopher, Matthew J., Ritchey, Julie K., Christ, Stephanie, Kim, Miriam Y., Bonvini, Ezio, DiPersio, John F.

“…•T-cell immunotherapies targeting AML antigens upregulate MHC-II expression on AML cells.•IFN-γ mediates the T-cell immunotherapy-induced MHC-II upregulation…”
Get full text